UFP Technologies Stock Price and Value Analysis

UFP Technologies (NasdaqCM:UFPT) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold UFP Technologies to reach your target.

Target type

UFPT Free Cash Flow Trend

Free Cash Flow trendline for UFPT
Free Cash Flow trendline for UFP Technologies
CSV

Based on historical returns, we believe that UFP Technologies can grow its free cash at a rate of about 7%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a decent rate.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company pays no dividend.

Inside the UFPT Numbers

UFPT Price
(UFP Technologies stock price per share)
$290.85
[?] UFPT Fair Price
(based on intrinsic value)
$58.74
[?] UFPT Safety Price (based on a variable margin of safety) $35.24
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 50% higher than other Healthcare stocks
[?] PE Ratio versus Industry 228% higher than other Medical Devices stocks
[?] Cash Yield 0.07%
[?] Free Cash Flow Jitter 89%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 913,963 shares shorted. With 7,479,947 shares available for purchase and an average trading volume over the past 10 trading days of 78,600, it would take at least 11.6 days for all of the short holders to cover their shorts.

What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 914156 10.3
2010 914156 10
2011 914156 9.2
2012 914156 11.3
2013 914156 11.1
2014 914156 3.5
2015 914156 2.4
2016 914156 -1.5
2017 914156 6.9
2018 914156 10.9
2019 914156 22.3
2020 914156 18.4
2021 914156 8
2022 914156 10.8
2023 914156 33.4
2024 914156 57.9
2025 914156 84

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 13 fiscal years from 2013 to 2025 with positive net income, operating cash flow totaled $376 million against net income of $321 million, or 1.17 times.

In 2025, operating cash flow was 1.35 times net income, compared with 1.50 times for the earliest three years (2013 to 2015).

In 2024, capital expenditures were $9.7 million, 14.5% of operating cash flow of $66.6 million, which leaves an estimated $56.9 million after capex. Across the 12 years with reported capex, it averaged 37.8% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2013 11.3 16.1 5.8 1.43
2014 7.6 11.1 13.4 1.47
2015 7.6 12.5 15.7 1.65
2016 8 9.3 7.2 1.17
2017 9.2 17.5 10.4 1.90
2018 14.3 21.3 5.4 1.49
2019 19.8 31.2 5.8 1.58
2020 13.4 25 4.4 1.87
2021 15.9 14.3 5.4 0.90
2022 41.8 17.7 13.8 0.42
2023 44.9 41.3 10.5 0.92
2024 59 66.6 9.7 1.13
2025 68.3 91.9 not reported 1.35

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $99.2 million in 2009 and $603 million in 2025, a compound annual growth rate of 11.9% over 16 years.

Revenue rose 19.5% from 2024 to 2025.

Our estimated free cash flow was $84 million in 2025, 13.9% of revenue. In 2009 the estimated margin was 10.4%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 99.2 10.3 10.4%
2010 121 10 8.3%
2011 127 9.2 7.3%
2012 131 11.3 8.6%
2013 139 11.1 7.9%
2014 139 3.5 2.5%
2015 139 2.4 1.7%
2016 146 -1.5 -1.1%
2017 148 6.9 4.7%
2018 190 10.9 5.7%
2019 198 22.3 11.3%
2020 179 18.4 10.3%
2021 206 8 3.9%
2022 354 10.8 3.1%
2023 400 33.4 8.3%
2024 504 57.9 11.5%
2025 603 84 13.9%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $20.3 million against total liabilities of $231 million, or 8.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 35.3% of total assets in 2025, compared with 27.7% in 2010, an increase of 7.6 percentage points.

Stockholders equity was $424 million in 2025, compared with $50.2 million in 2010, a rise of 743.9%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 15.0% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 69.5 22.1 19.3 50.2
2011 79.7 29.8 17.7 62
2012 98.6 33.5 25.4 73.3
2013 105 37.3 19.3 85.6
2014 113 34.1 17.6 95
2015 120 29.8 16.1 104
2016 128 31.4 14.9 113
2017 138 38 14.5 124
2018 190 3.2 49.1 140
2019 189 3.7 26.8 162
2020 203 24.2 26.3 177
2021 334 11.1 140 194
2022 378 4.5 141 238
2023 404 5.3 118 286
2024 629 13.4 286 343
2025 655 20.3 231 424

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $290.85, the price is above what our model can produce for average free cash flow growth between -30 and 60 percent a year, so no implied growth rate is shown. Our model assumes 7.0 percent a year for this stock. This is not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $1.6 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $232.68 above range
Current price $290.85 above range
20 percent above the current price $349.02 above range
Our model (stored fair price) $58.74 7.0%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

At $290.85, UFP Technologies trades above our fair value estimate of $58.74.

Of the 17 fiscal years we can see for UFP Technologies under its current filer, 16 show positive free cash flow.

Free cash flow from the first three years of data averaged $9.9 million, and from the last three $58.4 million: a sharp rise.

Free cash flow is volatile from year to year, with a variability measure of 89%.

Our value investing guide explains how to test these numbers against the filings themselves.

No dividend yield is recorded for UFP Technologies in our data.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 50% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 228% above the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to UFP Technologies, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
UFP Technologies (UFPT) 2,253 29.7 - 0.1% 395% above
LeMaitre Vascular (LMAT) 1,684 27.1 1.3% - 328% above
CONMED Corporation (CNMD) 1,382 19.2 - 5.6% 35% below
IRadimed Corporation (IRMD) 1,036 43.3 1.0% - 995% above
Tactile Systems Technology (TCMD) 573 24.9 - - 162% above
InfuSystem Holdings (INFU) 287 32.6 - - 402% above
Utah Medical Products (UTMD) 198 20.8 1.7% 6.7% 75% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 914156.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 1 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: UFPT annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in UFPT

Does UFP Technologies have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: UFPT

This example shows how we apply the Trendshare checklist to UFPT: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 290.85
    • Market cap: $2.3B
    • EPS: 9.79
  2. Step 2 — Valuation checks

    • P/E: 29.709
    • FCF yield: 0.1%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.